Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.48) per share which beat the ana

- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - D

- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery Sy

- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System

Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.52) per share which beat the ana

- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skinca

Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Fr

Dermata Therapeutics shares are trading higher Friday after the USPTO issued a notice of allowance f

Planet Labs (PL) stock rose in pre-market trading after better-than-expected Q4 sales and strong FY2

UPDATE: Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIO

- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand - SAN DIEG

Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) is expected to issue its results before the ma

-The oldest new thing in skincare - - Dermata expects to launch its first product in the middle of 2

The Company's innovative acne kit represents a new approach to acne treatment by targeting the u

This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combin

U.S. stock futures swung between gains and losses on Tuesday after Monday's declines. Futures of maj

U.S. stock futures swung between gains and losses on Tuesday after Monday’s declines. Futures of maj

U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, C

U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, C

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds up

Dermata Therapeutics rose after announcing a private placement offering of common shares, Series C w

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company")

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds up

SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ

Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.65) per share which missed the a

- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care